Skip to main content

Advertisement

Table 3 Disease activity, bone mineral density and laboratory variables in patients with juvenile idiopathic arthritis during tumour necrosis factor α blocker treatment and in control participants a

From: Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis

  0(n=31) 12 months(n=31) 24 months(n=31) Control participants(n=83)
hsCRP (mg/L) 12.09b 5.19b 4.28b 0.73
(6.28 to 25.17) (1.30 to 12.89) (0.89 to 13.44) (0.27 to 1.78)
ESR (mm/hr) 25.50b 16.00b 12.00b,c 4.00
(20.00 to 36.00) (4.00 to 24.00) (4.00 to 26.00) (2.00 to 8.00)
DAS28 6.26 2.93c 2.51c  
(5.87 to 6.82) (1.13 to 3.69) (1.25 to 3.64)  
Swollen joints (n) 12.0 0.0c 0.0c  
(9.0 to 15.5) (0.0 to 2.0) (0.0 to 2.0)  
Tender joints (n) 15.0 1.0c 0.0c  
(11.3 to 17.8) (0.0 to 2.0) (0.0 to 2.0)  
PGH (mm) 69.0 18.0c 10.0c  
(59.0 to 75.0) (5.0 to 27.8) (0 to 20.0)  
Lumbar spine BMD (g/cm2) 1.065b 1.089b,c 1.093b,c 1.209
(0.972 to 1.221) (1.044 to 1.248) (1.053 to 1.161) (1.175 to 1.279)
Femur total BMD (g/cm2) 0.909b 0.918b 0.886b 1.134
(0.776 to 0.984) (0.776 to 1.015) (0.790 to 0.996) (1.061 to 1.202)
Femoral neck BMD (g/cm2) 0.899b 0.903b 0.905b 1.118
(0.819 to 1.017) (0.806 to 1.033) (0.821 to 1.019) (1.042 to 1.201)
Distal forearm BMD (g/cm2) 0.690 0.712 0.707 0.713
(0.614 to 0.761) (0.638 to 0.769) (0.632 to 0.762) (0.676 to 0.768)
Osteocalcin (μg/L) 17.75 17.45 15.20 21.20
(12.40 to 24.80) (8.80 to 26.90) (11.95 to 20.20) (16.68 to 26.90)
PINP (μg/L) 46.16 46.41 51.23 50.96
(31.96 to 59.41) (32.01 to 88.77) (33.66 to 72.01) (37.10 to 81.84)
βCTX-I (μg/L) 0.35 0.33 0.33b 0.46
(0.18 to 0.52) (0.23 to 0.49) (0.20 to 0.45) (0.34 to 0.70)
sRANKL (pmol/L) 0.08 0.05 0.07 0.06
(0.02 to 0.25) (0.00 to 0.25) (0.00 to 0.21) (0.00 to 0.16)
OPG (pmol/L) 3.84 3.26 3.02 3.14
(2.53 to 4.84) (2.10 to 3.64) (2.03 to 3.55) (2.62 to 3.85)
sRANKL/OPG ratio 0.03 0.03 0.01 0.02
(0.01 to 0.07) (0.00 to 0.10) (0.00 to 0.10) (0.00 to 0.05)
Dkk1 (pmol/L) 28.74 24.08 21.52b,c 28.74
(23.8 to 36.84) (14.54 to 29.41) (15.72 to 31.25) (23.80 to 36.84)
Sclerostin (μg/L) 7.42b 2.06c 1.22c 1.94
(3.57 to 15.49) (1.00 to 3.48) (0.30 to 3.26) (0.62 to 5.71)
  1. aBMD: Bone mineral density; BMI: Body mass index; βCTX-I: C-terminal telopeptide of collagen type I; DAS28: Disease Activity Score in 28 joints; PGH: patient global health; Dkk1: Dickkopf Wnt signalling pathway inhibitor 1; ESR: Erythrocyte sedimentation rate; hsCRP: High-sensitivity C-reactive protein; JIA: Juvenile idiopathic arthritis; 25(OH)D: 25-hydroxyvitamin D3; OPG: Osteoprotegerin; PINP: Procollagen type I N-terminal propeptide; PTH: Parathyroid hormone; sRANKL: Soluble receptor activator of nuclear factor κB ligand. bMedian and 75% CI with probability P <0.05 by means of one-way analysis of variance, as compared to control participants. cMedian and 75% CI with probability P <0.05 by means of repeated-measures one-way analysis of variance within JIA group, as compared to baseline.